Intracerebroventricular drug administration

Atkinson, Arthur J.

doi:10.12793/tcp.2017.25.3.117

Cited by 47 publications

(36 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, we calculated both LS‐CSF volume and TLS‐CSF volume in pediatric patients for the first time. As LS‐CSF volume is one of the most important factors during spinal anesthesia and TLS‐CSF volume can be used to assess the pharmacokinetics of intrathecal medications, the results from this study will be helpful in understanding these issues of pediatric intrathecal medications.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Lumbosacral and thoracolumbosacral cerebrospinal fluid volume changes in neonates, infants, children, and adolescents: A retrospective magnetic resonance imaging study

Jang

Lee

Seo

et al. 2018

Pediatric Anesthesia

View full text Add to dashboard Cite

Summary Background The volume of cerebrospinal fluid can affect the pharmacokinetics and pharmacodynamics of local anesthetics for spinal anesthesia and other intrathecal medications. Aims The objective of this study was to estimate the lumbosacral cerebrospinal fluid volume and thoracolumbosacral cerebrospinal fluid volume using magnetic resonance images in pediatric patients from neonates and infants to adolescents. Methods Spinal magnetic resonance images of 500 pediatric patients (age <18 years) were reviewed. The lumbosacral cerebrospinal fluid volumes of 418 patients and thoracolumbosacral cerebrospinal fluid volumes of 248 patients were measured. The relationship between cerebrospinal fluid volumes and age, height, and weight were evaluated. The lumbosacral and thoracolumbosacral cerebrospinal fluid volumes per weight were calculated to elucidate developmental changes. Results The lumbosacral and thoracolumbosacral cerebrospinal fluid volumes showed linear correlations with height (r2 = 0.730 and r2 = 0.661, respectively), whereas they showed curvilinear correlations with age (r2 = 0.752 and r2 = 0.717, respectively) and weight (r2 = 0.734 and r2 = 0.734, respectively). The mean lumbosacral cerebrospinal fluid volume per weight (mL/kg) was 0.85 (standard deviation [SD]: 0.19, 95% confidence interval [CI]: 0.81‐0.90) in neonates and infants, 0.86 (SD: 0.22, 95% CI: 0.83‐0.89) in toddlers and preschoolers, 0.71 (SD: 0.26, 95% CI: 0.66‐0.76) in schoolers, and 0.54 (SD: 0.20, 95% CI: 0.49‐0.60) in adolescents. The mean thoracolumbosacral cerebrospinal fluid volume per weight (mL/kg) was 1.95 (SD: 0.37, 95% CI: 1.86‐2.04) in neonates and infants, 1.82 (SD: 0.41, 95% CI: 1.75‐1.88) in toddlers and preschoolers, 1.38 (SD: 0.40, 95% CI: 1.23‐1.52) in schoolers, and 0.99 (SD: 0.34, 95% CI: 0.45‐1.53) in adolescents. Conclusion The lumbosacral and thoracolumbosacral cerebrospinal fluid volumes in pediatric patients were much smaller than previously presented values, showing linear correlations with height, and demonstrate curvilinear correlations with age and weight.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The lumbosacral CSF (LS‐CSF) volume can affect intrathecal local anesthetics for spinal anesthesia. In addition, thoracolumbosacral CSF (TLS‐CSF) volume can affect intrathecal chemotherapy, and the administration of other novel intrathecal medications, such as antisense oligonucleotides for treating neurological disorders …”

Section: Introductionmentioning

confidence: 99%

Lumbosacral and thoracolumbosacral cerebrospinal fluid volume changes in neonates, infants, children, and adolescents: A retrospective magnetic resonance imaging study

Jang

Lee

Seo

et al. 2018

Pediatric Anesthesia

View full text Add to dashboard Cite

show abstract

“…While not investigated by the authors, it is likely that such a method of drug delivery would also affect the gut microbiome. Considering the link between intestinal dysbiosis and neurodegeneration, 118 such a method could affect treatment outcomes and a more localized way of drug delivery, potentially by intranasal 119 or direct intraventricular/intrathecal administration, 120 could minimize off-target effects.…”

Section: Alzheimer's Diseasementioning

confidence: 99%

Macrophage reprogramming for therapy

et al. 2021

View full text Add to dashboard Cite

Dysfunction of the immune system underlies a plethora of human diseases, requiring the development of immunomodulatory therapeutic intervention. To date, most strategies employed have been focusing on the modification of T lymphocytes, and although remarkable improvement has been obtained, results often fall short of the intended outcome. Recent cutting-edge technologies have highlighted macrophages as potential targets for disease control. Macrophages play central roles in development, homeostasis and host defence, and their dysfunction and dysregulation have been implicated in the onset and pathogenesis of multiple disorders including cancer, neurodegeneration, autoimmunity and metabolic diseases. Recent advancements have led to a greater understanding of macrophage origin, diversity and function, in both health and disease. Over the last few years, a variety of strategies targeting macrophages have been developed and these open new therapeutic opportunities. Here, we review the progress in macrophage reprogramming in various disorders and discuss the potential implications and challenges for macrophage-targeted approaches in human disease.

show abstract

“…Both are bolus injection of activechemotherapeutic agents and it is a placement of a biodegradable compounds, active-chemotherapeutic impregnated, wafer into a tumor resection cavity and it is based on the principle of diffusion to drive the drug into the infiltrated brain [17,18]. The drugs directly delivered into the brain parenchymal space or surrounding the spinal cord and drugs can be administered by [1,19]:…”

Section: Intracerebral Implants (Ic) or Injectionmentioning

confidence: 99%